Role of solute carriers in response to anticancer drugs by unknown
Li and Shu Molecular and Cellular Therapies 2014, 2:15
http://www.molcelltherapies.com/content/2/1/15REVIEW Open AccessRole of solute carriers in response to anticancer
drugs
Qing Li1,2 and Yan Shu1*Abstract
Membrane transporters play critical roles in moving a variety of anticancer drugs across cancer cell membrane, thereby
determining chemotherapy efficacy and/or toxicity. The retention of anticancer drugs in cancer cells is the result of net
function of efflux and influx transporters. The ATP-binding cassette (ABC) transporters are mainly the efflux transporters
expressing at cancer cells, conferring the chemo-resistance in various malignant tumors, which has been well documented
over the past decades. However, the function of influx transporters, in particular the solute carriers (SLC) in cancer cells, has
only been recently well recognized to have significant impact on cancer therapy. The SLC transporters not only directly
bring anticancer agents into cancer cells but also serve as the uptake mediators of essential nutrients for tumor growth
and survival. In this review, we concentrate on the interaction of SLC transporters with anticancer drugs and nutrients,
and their impact on chemo-sensitivity or -resistance of cancer cells. The differential expression patterns of SLC transporters
between normal and tumor tissues may be well utilized to achieve specific delivery of chemotherapeutic agents.
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Membrane transporters play critical roles in moving a
myriad of endogenous and exogenous substances across
cellular and organelle membranes, including the major
nutrient metabolites sugars, digested peptides, amino
acids and nucleosides, rare elements such as hormones
and neurotransmitters, and xenobiotics. These transporters
are encoded by numerous gene families, accounting for ap-
proximately 4% of genes in human genome [1]. Clinically
used drugs usually have similar physiochemical structures
with certain endogenous substrates. In the last two de-
cades, a variety of membrane transporters have been
recognized as drug transporters. These drug transporters
are of essential importance in determining drug pharmaco-
kinetics, efficacy and adverse effects. Based on the driving
force, drug transporters are characterized by two major
superfamilies, the solute carriers (SLC) and the ATP-
binding cassette (ABC) transporters which can each be
functionally classified into influx and efflux transporters
according to the direction of movement of substrates
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unless otherwise stated.As reviewed elsewhere, the ABC transporters, which
are typical efflux drug transporters using energy from
the hydrolysis of ATP as the driving force to move
substrates against the electrochemical gradients outward
or into intracellular organelles. The 49 ABC transporters
can be classified into 7 subfamilies from A to G subfamily
[2-5]. In the past two decades, accumulating evidence
has shown that enhanced expression of several ABC
transporter genes is associated with reduced cellular
accumulation of anticancer drugs and acquired multi-
drug resistance in many human cancer cells. Those
ABC transporters of importance in cancer therapy have
been well documented for ABCB1 (or MDR1), ABCC1 (or
MRP1), ABCC2 (or MRP2), and ABCG1 (or BCRP) [6-8].
By contrast, the impact of the solute carriers (SLC), which
are usually influx or bi-directional transporters, on cancer
therapy has not been extensively characterized. In this re-
view, we provide updates on the documented interaction
of SLC transporters with anti-cancer drugs.
More than 400 SLC transporter genes have been identi-
fied and grouped into 55 families, including ion coupled
transporters, exchangers and passive transporters located
at the plasma membrane or in intracellular organelles
(e.g. mitochondrial or vesicular transporters) [9]. Unlike
ABC transporters which driving energy is provided bytd. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Schematic model of the transporters in major organs responsible for drug disposition. The SLC members reviewed here may play an
important role in determining the pharmacokinetics of anti-cancer drugs. They may be involved in drug absorption at the intestine, drug uptake into the
liver for metabolism, drug elimination in the kidney, and drug distribution in a variety of additional tissues such as heart, lung, and brain. To facilitate
understanding of drug transport processes in the organs, important efflux ABC transporters, which are reviewed elsewhere, are also depicted. Influx SLC
transporters are shown as yellow open ovals and efflux SLC transporters as green open ovals. Some SLC transporters which mediate bi-directional
transport are depicted by blue open ovals. ABC transporters are shown in black ovals. Black solid arrows indicate the direction of drug transport.
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passive diffusion along the concentration gradient of the
substrate or by co-transport and counter-transport against
the concentration gradient of another solute. The super-
family of SLCs is responsible for mediating the transport
of a wide spectrum of substrates, including different nutri-
ents as well as drugs [10].
The SLC transporters expressed in the small intestine,
the liver, and the kidney may be of particular importance
for the disposition of cancer drugs. Interindividual vari-
ation in the activities of these transporters may cause
altered pharmacokinetic profiles of anticancer drugs, sub-
sequently leading to variability in the pharmacodynamic
effects. The SLC transporters expressed in cancer cells
play an important role in cellular uptake of cancer drugs,
which may be a determinant step toward anti-cancer effi-
cacy. Indeed, cancer cells are more likely to show substan-
tially different expression profiles of SLC transporters as
compared to those of normal cells. Moreover, by mediating
the transport of essential nutrient molecules and modulat-
ing the electrochemical gradient across the membranes,
SLC proteins can function to modify the efficiency of drug
diffusion into cells or alter cell survival pathways, conse-
quently influencing chemotherapeutic efficacy (sensitivity
or resistance). In certain cases, cancer cells may possess
enhanced expression of SLC transporters for certain nutri-
tional requirements and take a growth advantage over nor-
mal cells when nutrients become restricted (Figure 2).To improve outcomes of cancer therapy, it is necessary
to fully characterize the function of SLC drug transporters
in the organs critical to the disposition of anti-cancer
drugs, such as intestine, liver and kidney. Moreover, by
understanding the altered expression of SLC transporters
in various cancer cells, we may develop novel therapeutic
strategies to treat cancers. For instance, transporter-
targeted chemotherapy may be achieved via down-
regulation of certain essential transporters for cancer
cell survival. The major subfamilies of SLC members,
which are, to different extents, explored in their associ-
ation with cancer therapy, include the following: folate
transporters (SLC19A1 and SLC 46A1), which are par-
ticularly important for antifolate chemotherapy of cancer
and reviewed elsewhere [11-13]; organic cation trans-
porters (OCT) (SLC22A1-3); organic anion transporters
(OAT) (SLC22A6-8); organic cation/carnitine transporters
(SLC22A4-5); organic anion transporters polypeptides
(OATPs) (SLCO); copper transporters (SLC31A); multi-
drug and toxin extrusion proteins (MATEs) (SLC47A),
which intriguingly function as efflux transporters in cer-
tain tissues; oligopeptide transporters (SLC15A1/2); and
amino acid transporters (SLC7A and SLC3A) (Figure 3).
Organic cation transporters (OCT)
Organic cation transporters consist of three isoforms
(OCT1/SLC22A1, OCT2/SLC22A2, OCT3/SLC22A3),
which mediate the transport of various organic cations,
Figure 2 Schematic model of development of anticancer drug resistance due to altered expression of transporters. SLC transporters
(OCTs, OATs, CTR, and OATPs in green open ovals) may take up anticancer drugs into the cancer cells, while some ABC transporters (MDR1,
MRP1, MRP3, and BCRP in blue open ovals) may extrude them. In addition, certain SLC transporters (PEPTs, LATs, and ATA1 in yellow open ovals)
mediate the uptake of nutrients (e.g., amino acids and peptides) into cancer cells for their survival. The decreased expression of SLC transporters
(black bold arrow) responsible for drug uptake or/and the increased expression of ABC transporter (purple bold arrow) for drug efflux make the
cancer cells more resistant to anticancer drugs. The increased expression of SLC transporters (blue bold arrow) responsible for nutrient uptake
may also cause more resistant to anticancer drugs as the cancer cells have an advantage of survival from limited nutrient supply.
Li and Shu Molecular and Cellular Therapies 2014, 2:15 Page 3 of 14
http://www.molcelltherapies.com/content/2/1/15weak bases, and some neural compounds across plasma
membranes [14,15]. These transporters are facilitative
diffusion systems, and the driving force is provided by
the electrochemical gradient of the transported com-
pounds [16].Figure 3 Classified subfamilies of SLC transporters involved in respon
drugs reviewed in this article are included.OCT1
Human OCT1 (SLC22A1) is predominantly expressed in
the liver where it is located in the sinusoidal membrane
of the hepatocytes [17]. In rat, mouse, and rabbit, be-
sides high expression in the liver, strong expression wasse to anticancer drugs. Only the SLC members and the anticancer
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basolateral membranes of S1 and S2 segments of proximal
tubules [18]. Human OCT1 is expressed to a much lesser
extent in various additional organs including kidney, small
intestine, lung, heart, skeletal muscle, brain, placenta,
mammary gland, adrenal gland, eye, adipose tissue, and
immune cells [18-23], and differentially expresses in vari-
ous tumors [18,24,25].
OCT1 has been showed to be expressed in colon can-
cer and polyps [26]. Specifically, it has been reported
that OCT1 mRNA level is increased in human colon
cancer cell lines and patient-derived colorectal tumor
samples [27]. Platinum-based drugs, including cisplatin
and oxaliplatin, are efficient to induce DNA damage by
forming DNA adducts and subsequently cause apoptosis
in colon cancer cells. Cisplatin has shown a high specifi-
city and affinity for OCT1 with an IC50 (half maximal in-
hibitory concentration) value of 8.1 uM. However, Zhang
et al. reported that human OCT1 markedly increased oxa-
liplatin, but not cisplatin, accumulation and cytotoxicity in
the stable cells expressing OCT1 transporter and oxalipla-
tin was an excellent substrate of OCT1 [28]. The cytotox-
icity by oxaliplatin was also much greater than that of
cisplatin in the colon cancer cells. By using an OCT in-
hibitor, cimetidine, they demonstrated that the function of
OCTs such as OCT1 and OCT2 is a major determinant of
the anticancer activity of oxaliplatin, which may be causa-
tive of its specificity of anti-colon cancer. Picoplatin, a
third-generation platinum agent, is efficacious against lung
cancers that become refractory to other platinum-based
treatment. More et al. reported that the tumor size of
OCT1-expressing xenografts in mice was significantly
reduced by picoplatin treatment as compared to control
xenografts, which suggested that OCT1 could enhance
the antitumor efficacy of picoplatin as well [25].
OCT1 has also been demonstrated to be significantly
expressed in chronic myeloid leukemia (CML) cell lines
and primary CML cells [29]. Imatinib, a potent tyrosine
kinase inhibitor, is used to treat CML. OCT1 has been
reported to mediate the transport of imatinib mesylate
across cellular membrane. Considerable evidence has
revealed that OCT1 expression level in leukemic cells is
associated with the therapeutic outcome in CML [30-35].
It has been reported that OCT1 activity may be a key de-
terminant of molecular response to imatinib [36]. By using
a potent inhibitor such as prazosin, the activity of OCT1-
mediated imatinib transport can be determined in vitro in
the isolated peripheral blood leukocytes from CML pa-
tients. This measurement of OCT1 function may be useful
to individualize dosage regimens for patients with CML in
order to obtain an optimal outcome in the long-term
imatinib-treated patients [36].
In addition, the antineoplastic agents irinotecan, mitox-
antrone, and paclitaxel were found to inhibit the uptake ofthe organic cation 3H-1-methyl-4-pyridinium iodide into
Chinese hamster ovary cells that are overexpressed with
human OCT1, with Ki values of 1.7, 85, and 50 μM, re-
spectively [24]. The OCT1-transfected cells also exhibited
significantly more susceptible to the cytotoxicity of irino-
tecan and paclitaxel when compared with mock cells, sug-
gesting that OCT1 may contribute to accumulation of the
selected antineoplastic drugs in cancer cells. The expres-
sion of OCTs in various tumors should be further investi-
gated as it may serve as a biomarker for selecting specific
antineoplastic agents to tailor cancer therapy for individ-
ual patients.
OCT2
The cloning of Slc22a2 encoding Oct2 from rat was re-
ported in 1996 [37]. OCT2 orthologs were later cloned
from other species including humans [14,38]. Human
OCT2 (SLC22A2) is mainly expressed at the basolateral
membrane of renal proximal tubules in the kidney [14],
and its expression is also detectable in small intestine,
lung, placenta, thymus neurons, choroid plexus, inner
ear, and respiratory mucosa [39,14].
OCT2 mediates the first step of many cationic drugs
in renal excretion via their uptake at the basolateral
membrane of proximal tubule cells. As for anticancer
drugs, cisplatin has been demonstrated to be a substrate
of OCT2, evidenced by significantly higher uptake of cis-
platin in OCT2 overexpressing cells compared with that
in mock cells [39]. Abundant evidence indicates that cis-
platin accumulates in the proximal tubules and causes
nephrotoxicity. Human OCT2 transporter has been re-
ported to mediate the transport of cisplatin across proximal
tubules membrane from circulation [40], and is critical to
the nephrotoxicity of cisplatin. A non-synonymous single-
nucleotide polymorphism (SNP, rs316019) in the OCT2
gene has been demonstrated to be associated with de-
creased nephrotoxicity of cisplatin in patients [40].
Moreover, the mice lacking of Oct2 function have reduced
urinary excretion of cisplatin and less cisplatin-induced
nephrotocixity [40]. In addition, the wild-type mice treated
with cisplatin plus the OCT inhibitor cimetidine have a re-
duced nephrotoxicity similar to that seen in Oct1/2-/-
double knockout mice treated with cisplatin alone [41]. It
seems that a reduced uptake by transporters such as OCT2
at the basolateral membrane in the proximal tubules is
likely to protect kidney from cisplatin-induced nephrotox-
icity. Oxaliplatin has also been considered as a substrate of
OCT2. However, it does not induce severe nephrotoxic ef-
fects similar to cisplatin [42]. This may be explained by
another protein transporting organic cations, the kidney
isoform of MATE2 (MATE2K). MATE2K (SLC47A2) is
located at the apical membrane of proximal tubules and
can specifically remove oxaliplatin, not cisplatin, from the
proximal tubules [43-45]. In addition, the third-generation
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cantly enhance cytotoxicity in the presence of OCT2 ex-
pression with increased DNA adduct formation [25].
These studies underscore the importance of OCT2 func-
tion in renal disposition and possible tumor accumulation
of platinum compounds in platinum-based chemotherapy.
OCT3
The SLC22A3 gene encoding OCT3 was independently
cloned as the extraneuronal monoamine transporter by
different groups [46,47]. Unlike human OCT1 and OCT2
with high expression in limited tissues, human OCT3 is
ubiquitously expressed [15,18,48] with relatively high
expression in the heart, skeletal muscle, brain, liver, and
kidney [14,47,49]. Specifically, human OCT3 is located
to the basolateral membrane of placental epithelium
[50], the sinusoidal membrane of hepatocytes [17], and
the luminal membrane of bronchial epithelial cells [18].
Human OCT3 has differential expression between nor-
mal and cancerous tissues. An upregulated OCT3 expres-
sion was observed in the cancerous tissues of colon
rectum and stomach as compared to the normal tissues,
however, significantly decreased expression was found
in several other cancerous tissues, including uterus,
breast, ovary and lung cancers [51]. It has been reported
that oxaliplatin is a substrate of OCT3, in contrast to
carboplatin, which are not substrate of OCT3 [43,44].
OCT3 moderately transports oxaliplatin and can medi-
ate oxaliplatin-induced cytotoxicity in cell cultures [51].
Yokoo et al. reported that the effect of oxaliplatin
against colorectal cancer was superior to that of cisplatin
because OCT3 was highly expressed when compared with
other organic cation transporters [51]. Recent studies have
showed that other cytostatics, such as melphalan, irinote-
can, and vincristine [52], may interact with OCT3 as well.
Irinotecan, which is well used to treat colon carcinoma,
exhibits a high affinity for OCT3, and its increased cyto-
toxicity in kidney carcinoma cell lines was associated with
OCT3 expression. These results suggested that human
OCT3 expression may be further evaluated as a potential
biomarker for the efficacy of cancer chemotherapy.
Organic anion transporters (OAT)
Organic anion transporters (OATs), also members of the
solute carrier family 22, play a key role in renal excretion
of water-soluble, negatively charged organic compounds
[53]. Renal OATs are expressed in the baselateral mem-
branes of proximal tubular cells, the major site for secreting
organic anions in the kidney. OATs are also expressed in
other tissues, including liver, placenta, nasal epithelium,
and blood-brain barrier. In humans, OAT subfamily con-
sists of OAT1–4, OAT7, OAT10, and URAT1 (SLC22A16).
Several classes of drugs interact with human OAT1-3, in-
cluding ACE inhibitors, angiotensin II receptor antagonists,diuretics, HMG CoA reductase inhibitors, β-lactam antibi-
otics, antiviral drugs, uricosuric drugs, and antineoplastic
drugs. In this review, we focus on OAT1-3, whose role in
drug disposition and cancer therapy has been investigated
relatively well.
OAT1
The organic anion transporter 1, OAT1 (SLC22A6), was
the first OAT member which was cloned from rat [54],
mouse [55], and later human [56,57]. Human OAT1 was
localized to the basolateral membrane of renal proximal
tubule cells by immunocytochemistry and was found
along the whole proximal tubule [57-59]. This expres-
sion pattern is consistent with the role of OAT1 in the
uptake of anionic drugs from the circulation into prox-
imal tubule cells. OAT1 has also been detected in the
brain, specifically in the choroid plexus [60].
Human OAT1 has been reported to be responsible for
renal tubular secretion of methotrexate which is an antifo-
late used in the treatment of malignancies [61]. Metho-
trexate is also transported by rat and mouse Oat1 with a
moderate to high affinity [62,63]. Clinical interaction be-
tween methotrexate and other drugs such as loxoprofen
has been well documented. Interestingly, loxoprofen and
its trans-OH metabolite, the major active metabolite,
markedly inhibit the transport of methotrexate by OAT1.
In clinical chemotherapy, high doses of methotrexate are
frequently used, and methotrexate-induced severe nephro-
toxicity has been well documented. OAT-mediated uptake
of methotrexate into tubule cells may significantly contrib-
ute to its nephrotoxicity. Reports are also available suggest-
ing that the cytotoxicity and anticancer effects of several
other antineoplastic agents, including 6-mercaptopurine,
azathioprin, cisplatin, imatinib, cytarabine, vinblastine, vin-
cristine, hydrocortisone, and mitoxantrone, may be associ-
ated with OAT1 expression [64,65].
OAT2
Liver and kidney have the highest expression level of
OAT2, and relatively low expression level of OAT2 was
found in pancreas, small intestine, lung, brain, spinal cord,
and heart. [66-69]. However, the expression of OAT2
mRNA is much lower than those of OAT1 and OAT3
mRNAs In human kidneys. [67]. OAT2 is located in the
sinusoidal membrane of hepatocytes [70] and the basolat-
eral membrane of proximal tubule cells [71].
As a major hepatic transporter, OAT2 plays an important
role in hepatic drug uptake, which may be a determinant of
metabolism for various anticancer drugs. 5-fluorouracil,
which is used in colorectal and pancreatic cancer therapy,
is a verified substrate of OAT2 [72]. In the same study,
Kobayashi et al. also reported that paclitaxel was an OAT2
substrate [72]. Tanino et al. later showed a concentration-
dependent uptake of paclitaxel in rat hepatocytes [73].
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did not significantly inhibited the uptake of paclitaxel,
which suggested that Oat2 was not a significant transporter
for the hepatic uptake of paclitaxel, at least in rat hepato-
cytes [73].
OAT3
OAT3 (SLC22A8) has been cloned from human, monkey,
pig, rabbit, rat, and mouse. In these species, OAT3 mRNA
is detected in a variety of tissues or organs including
kidney, liver, brain, skeletal muscle, and adrenal glands
[65,74]. In all tested species, the kidney has the highest
mRNA expression of OAT3 among all organs [21,74].
The transporter protein is located at the basolateral mem-
brane of proximal tubule cells in the kidney [38,75].
Methotrexate (MTX) has a 30-fold stronger affinity to
OAT3 with the Km value of 17.2 μM as compared with
OAT1 (Km: 724 μM) [61]. Thus, human OAT3 could be
mainly responsible for the renal MTX excretion and
MTX-induced nephrotoxicity during cancer therapy.
Among interactions between anticancer drugs and OAT3,
6-thioguanine was found to inhibit rat Oat3 (IC50 172
μM), 6-mercaptopurine could be transported by both rat
and mouse Oat3 (Km: 50.5 μM and 4 μM, respectively),
and 5-fluorouracil was substrate of mouse Oat3 (Km:
0.054 μM) [76,64]. In addition, rat Oat3 (Km: 21.9 μM)
and human OAT3 (Km: 56.5 μM) translocated topotecan
with a moderate affinity [77].
Organic cation/carnitine transporters (OCTN1-2 and OCT6)
Organic cation/carnitine transporters comprise the trans-
porters OCTN1, OCTN2 and OCT6, encoded by the
genes SLC22A4, SLC22A5 and SLC22A16, respectively
[18]. The three transporter genes have a broad expression
pattern in normal tissues. Some human tumor-derived cell
lines, including lung carcinoma A549, colorectal carcin-
oma SW480, and cervix carcinoma Hela S3 cells, have
been detected to express high levels of OCTN1 and
OCTN2 transcripts [78,79]. Human OCT6 expression has
been determined from testis, hematopoietic cells, and
leukemia lines HL-60 and MOLT4 [80-82].
Human OCTN1 mediates uniport of organic cations
such as the antioxidant ergothioneine as well as H+/or-
ganic cation antiport, whereas human OCTN2 and OCT6
are Na+/carnitine cotransporters as well as organic cation
uniporters [18]. Recently, by conducting uptake studies in
the HEK293 cells over-expressing rat Octn1, rat Octn2,
human OCTN1, and human OCTN2, Jong et al. reported
that the transport of oxaliplatin across cellular membrane
could be mediated by OCTN1 and OCTN2. Both the up-
take and cytotoxicity of oxaliplatin were well inhibited by
ergothioneine and L-carnitine. Importantly, they provided
evidence supporting that the transport of oxaliplatin me-
diated by OCTN1 appeared to mainly contribute to itsneuronal accumulation and treatment-limiting neurotox-
icity [83].
OCTN2 has been recently suggested by Hu et al. as an
efficient and capable transporter for imatinib at a con-
centration (e.g., 0.2 μmol/L) [84] that is readily achiev-
able in human patients [85]. Furthermore, among the
patients of gastrointestinal stromal tumors (GIST) who
received imatinib treatment, the time to progression was
recently shown to be significantly improved in the carriers
of the C allele of an OCTN1 polymorphism (rs1050152)
as well as in carriers of minor alleles of two OCTN2 poly-
morphisms (rs2631367 and rs2631372), suggesting the
activities of OCTN1 and OCTN2 as a predictor of chemo-
therapeutic efficacy of imatinib [86].
Doxorubicin is a widely used anticancer drug for
hematological malignancies, particularly for acute lympho-
cytic leukemia (ALL) and acute myeloid leukemia (AML).
OCT6 has been found by Okabe et al. to mediate the
uptake of doxorubicin in leukemic cells and the stable
leukemic Jurkat cells with over-expression of OCT6 gene
became more sensitive to doxorubicin. In the same report,
OCT6 expression was detected in the primary blood cells
collected from the patients with acute leukemia [81]. Bleo-
mycin is widely used in combination with other antineo-
plastic agents to effectively treat lymphomas, testicular
carcinomas, and squamous cell carcinomas of the cervix,
head, and neck. OCT6 has also been found to be involved
in the uptake of bleomycin-A5 as well as polyamines.
Human testicular cancer cells overexpressing OCT6 were
extremely sensitive to bleomycin-A5 and the siRNA tar-
geted OCT6 induced significant resistance to bleomycin-
A5-dependent genotoxicity. The knowledge of OCT6
function remains relatively limited. These recent findings
suggest that characterizing OCT6 expression in human
cancer cells may be valuable for us to improve current
chemotherapy and explore novel cancer therapeutic strat-
egies [87].
Organic anion transporting polypeptides (OATP, SLCO)
There are 11 known human OATPs which have been
divided into six subfamilies based on their amino acid
sequence similarities [88-91]. OATPs expression can be
either tissue-specific or ubiquitous in multiple tissues
throughout the body. Among the OATP family mem-
bers, OATP1A2, OATP1B1, OATP1B3 and OATP2B1
have broad substrate specificity and accept a number of
therapeutic agents. Latest studies have demonstrated that
OATP expression is differently regulated in certain cancer
tissues as compared to normal tissues. The OATP1 sub-
family is the most characterized among the OATPs. It
should be pointed out that very different subfamily mem-
bers of SLCO/Slco have been evolved between humans
and rodents. This is particularly true within the OATP1
family as there are no clear orthologs between individual
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OATP1A transporter (OATP1A2), but mice have at least
4 (Oatp1a1, Oatp1a4, Oatp1a5, and Oatp1a6) [89,92]. In
addition, while humans have 2 OATP1B transporters
(OATP1B1 and OATP1B3), mice only have Oatp1b2 [92].
In this section, we focus on the interaction of OATP1 with
anticancer drugs.
OATP1B1
OATP1B1 (SLCO1B1) is highly expressed in human liver
[93-95]. Further, the transporter gene profiling assay in
NCI-60 cancer cell lines showed relatively high expres-
sion of OATP1B1 in the cells derived from lung cancers,
such as A549 and EKVX cells, and colon cancers, such
as HCT-15 and KM12 cells [96]. In addition, the mRNA
level of OATP1B1 was found to be higher in colon
polyps and cancer tissues as compared with normal
colon tissues [26].
OATP1B1 activity may be important in hepatic dispos-
ition of anticancer drugs. Nozawa et al. firstly reported
that OATP1B1 is responsible for hepatic uptake of SN-38,
the major active metabolite of irinotecan and that the gen-
etic polymorphisms of OATP1B1 may contribute to the
well-known individual variation in the disposition of iri-
notecan [97]. Later, in a case report, severe irinotecan
toxicity was observed in a 66-year-old Japanese with
dysfunctional alleles of OATP1B1 [98]. The toxicity is
possibly due to a decreased uptake of active metabolite
(SN-38) of irinotecan into the liver and subsequently
reduced hepatic metabolism. It has been demonstrated
that in OATP1B1 transgenic mice, the hepatic accumu-
lation of MTX was significantly higher (approximately
2-fold) compared with wild-type mice after MTX treat-
ment, resulting in 2- to 4-fold higher liver-plasma ratios
of MTX. The findings suggest a marked and possibly
rate-limiting role for human OATP1B1 in MTX elimin-
ation in vivo [99]. In addition, polymorphisms in the
OATP1B1 gene were found to be associated with the
disposition and therapeutic outcomes of flavopiridol and
atrasentan [100,101].
OATP1B3
OATP1B3 (SLCO1B3), normally and specifically expressed
in liver, has been found in different cancer tissues [102].
Specifically, OATP1B3 is upregulated in gastrointestinal
cancer cell lines, pancreatic cancer cell lines, and gallblad-
der cancer cell lines. OATP1B3 expression was dramatic-
ally higher in colorectal adenocarcinoma tissues and in
prostate cancer tissues as compared with their corre-
sponding normal tissues [103-105].
Hu et al. found a significantly higher uptake rate for
[3H] imatinib in HEK293 cells transfected with human
OATP1B3 gene and in Xenopus laevis oocytes injected
with OATP1B3 cRNA [84]. Methotrexate has also beendemonstrated as an OATIP1B3 substrate as OATP1B3
transports methotrexate in a saturable and dose-dependent
manner. The introduction of the OATP1B3 gene into mam-
malian cells potentiates their sensitivity to methotrexate
[106]. In Xenopus laevis oocytes injected with OATP1B3
cRNA, the uptake of docetaxel and paclitaxel were 2.2-fold
and 3.3-fold higher, respectively, than that of water-injected
control oocytes [107,108], suggesting both drugs as
OATP1B3 substrates. However, in screening interaction
between OATP1B3 and a variety of compounds, although
docetaxel, paclitaxel, and three other antineoplastic
agents, actinomycin D, mitoxantrone, and SN-38 exhibited
potent inhibitory effects on OATP1B3-mediated transport
of CDCA-NBD (chenodeoxycholyl-(Nepsilon-NBD)-lysine,
a fluorescent substrate of OATP1B3)) [109], only SN-38
was further determined as a novel substrate for OATP1B3
[110]. Overall, OATP1B3 may be a clinically relevant
transporter responsible for hepatic disposition and the
chemotherapeutic response in cancer tissues of certain
anticancer drugs.
OATP1A2
Among normal tissues, OATP1A2 (SLCO1A2) is expressed
in the intestinal epithelium [111], the renal epithelium,
and highly in brain capillary endothelial cells. [112]
Altered OATP1A2 expression has been detected in
glioma, colon polyps and cancers, and breast cancers
as compared to normal tissues. In addition, OATP1A2
mRNA were found both in bone metastases from pri-
mary kidney cancer and in the malignant osteosarcoma
cell lines HOS and MG-63 [113].
Paclitaxel has been characterized as an OATP1A2 sub-
strate. When compared to wild-type mice, the transgenic
mice overexpressing human OATP1A2 had a remarkable
increased hepatic uptake of paclitaxel [114]. Further-
more, the systemic exposure of paclitaxel after an intra-
venous dose (10 mg/kg) was increased by greater than
2-fold in Slco1a/1b (-/-) mice compared with wild-type
mice, whereas its hepatic uptake was reduced by about
2-fold [115]. There is in vivo evidence supporting
methotrexate (MTX) as a substrate of OATP1A2 as
well. When compared with wild-type mice, Slco1a/1b
(-/-) mice exhibited a 3.4-fold increase in plasma and
30-fold decrease in hepatic levels of MTX after received a
high dose of 500 mg/kg, suggesting an overall role of
OATP function in MTX disposition [115]. Moreover, hu-
manized OATP1A2 transgenic mice showed significant
rescue of the increased plasma levels and decreased liver
and small intestinal accumulation of MTX that were ob-
served in Slco1a/1b (-/-) mice [114], confirmed MTX as
an OATP1A2 substrate. OATP1A2 has been extensively
detected in primary and metastatic liver cancers. As
the transporter could be a critical mediator of drug up-
take in the liver, OATP1A2 may be further exploited
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cancers [116].
Copper transporters (CTR, SLC31A)
Copper is a vital mineral for humans as demonstrated by
serious health concerns associated with its deficiency or
excess accumulation. Copper transporter 1 (CTR1) is the
major high-affinity copper uptake transporter in mammals
[117]. CTR1, encoded by the SLC31A1 gene, is localized
in the plasma membrane and intracellular membranes
[118,119]. CTR1 protein is ubiquitously expressed in
many tissues such as hepatocytes, α cells of the pancreatic
islets, enteroendocrine cells of the gastric mucosa and
bronchioles, c cells of the thyroid, and a subsets of cells
in the anterior pituitary [120]. It is also observed to be
expressed in both normal colonic epithelium and colon
carcinomas [120]. In addition, strong expression has
been found in a few cases of carcinoid tumors, Ewing’s
sarcoma, undifferentiated carcinomas, and enteroen-
docrine cells [120].
Abundant evidence has been consistently showed that
CTR1 is an important determinant of cellular accumula-
tion and toxicity of platinum-based anti-cancer drugs,
such as cisplatin [121-123]. Stable overexpression of hu-
man CTR1 significantly increased the uptake of cisplatin,
carboplatin and oxaliplatin in human small cell lung
cancer cell lines and rendered the cells more sensitive
to the cytoxicity of these compounds [124,125]. In con-
trast, small interfering RNA (siRNA)-mediated knock-
down of CTR1 was shown to be able to reduce both
cellular platinum accumulation and cytotoxicity of cis-
platin in human embryonic kidney 293 cells [126]. In
addition, mouse embryonic fibroblasts (MEF) of heterozy-
gous (+/-) and homozygous (-/-) Ctr1 gene deletion accu-
mulated 35% and 70% less platinum and exhibited 4- and
8-fold more resistant to cisplatin cytotoxicity after a 2
hour cisplatin exposure, respectively, than the wild-type
MEF cells [121]. Taken together, these studies have pro-
vided strong evidence in support of CTR1 role in mediat-
ing the uptake of cisplatin into normal and tumor cells.
Further clinical studies are needed to clarify how import-
ant the transporter function is in determining the antican-
cer efficacy and the toxic side effects of platinum-based
treatment in patients.
Multidrug and toxin extrusion (MATE) proteins (SLC47A)
Multidrug and toxin extrusion (MATE) proteins were
first found in bacteria in 1998 [127]. In 2005, the human
ortholog, MATE1, was first cloned and characterized as
an efflux transporter mediating the excretion of organic
cations from the kidney [128]. MATE2 and MATE2-K
were identified shortly thereafter. The driving force for
MATE is provided by the oppositely directed proton
gradient [128]. MATE proteins exist in various livingorganisms, including prokaryotes, plants and mammals,
and they are responsible for the transport of various
endo-/exogenous substrates. In humans, MATE1 is highly
expressed in the kidney and liver, which is localized at the
apical membrane of proximal tubules and hepatocytes.
Human MATE1 is also detectable in other tissues, in-
cluding adrenal gland, skeletal muscle, testis, and first
trimester placenta [129,130]. MATE2 and MATE2-K are
mainly expressed in the kidney [131].
Otsuka et al. reported that MATE1 mediates the ex-
cretion of cisplatin in the kidney [128]. It has been lately
reported by Nakamura et al. that cisplatine significantly
increased the levels of plasma creatinine and blood urea
nitrogen (BUN), two major biomarkers for renal injury,
in Mate1-deficient (Mate1-/-) mice when compared with
wild-type mice [132]. Further, the levels of creatinine
and BUN in the mice treated with cisplatin were signifi-
cantly enhanced by pyrimethamine, a potent MATE in-
hibitor [132]. Li et al. later reported that much severer
nephrotoxicity of cisplatin was observed in Mate1-/- mice
than in wild-type mice [133]. Thus, reduced function of
MATEs, which serves as efflux transporters for cisplatin
elimination in the kidney, may be responsible for
cisplatin-induced nephrotoxicity. In addition to cisplatin
as a substrate of MATE1, oxaliplatin was reported to be
transported by rat Mate1 as well as human MATE1 and
MATE2-K [134].
Oligopeptide transporters (PEPT1/2, SLC15A1/2)
The oligopeptide transporters (PEPTs, SLC15A) serve as
integral membrane proteins for mediating the cellular
uptake of di- and tripeptides into cells. Their driving
force comes from an inwardly directed H+ gradient
across the membrane [135]. PEPT1 and PEPT2 are two
major PEPTs that have been cloned. Physiologically,
PEPTs are localized at brush-border membranes of in-
testinal and renal epithelial cells, and play important
roles in protein absorption and the conservation of
peptide-bound amino nitrogen. Peptide-like drugs with
structural similarities to di- and tripeptides are also
transported by PEPTs [136]. PEPT1, a high-capacity
but low affinity transporter, mainly expressed in the
small intestine, whereas PEPT2, a high-affinity but
low-capacity transporter, broadly expressed in a variety
of tissues [135].
PepT1 and PepT2 were interestingly found to be
expressed in fibroblast-derived tumor cells but not in
normal fibroblasts [137]. High levels of PEPT 1 protein
were also detected in two human pancreatic cancer cell
lines, AsPc-1 and Capan-2 [138]. In addition, PEPT1
mRNA was increased 2.3-fold in colon cancer tissues
as compared to normal tissues [139]. Many peptide-
mimetic agents are the substrates of PEPTs. The higher
expression of PEPTs in cancer cells may serve as the basis
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mimetic anticancer drugs into tumors.
Bestatin, a potent aminopeptidase inhibitor and a
known substrate of PEPT1, suppressed the growth of
tumor (Hela cells) xenografts overexpressing PEPT1 by
4-week consecutive oral administration [140]. The high
expression of PEPTs in various cancer tissues has been
attributed to increased nutrients demand by fast tumor
growth, and thus inhibition of the activity of PEPTs
might be also a novel targeting strategy to delay or stop
tumor growth. Mitsuoka et al. found that a newly syn-
thesized dipeptide, 4-(4-methoxyphenyl)-L-phenylalanyl
sarcosine which was an inhibitor of PEPT1, resulted in
nearly complete suppression of the xenograft growth of hu-
man pancreatic cancer AsPC-1 cells that highly expressed
PEPT1 [141].
Floxuridine, a clinically proven anticancer drug, is
commonly used for the treatment of metastases from
colon carcinomas and hepatocellular carcinoma [142].
In order to improve its selectivity and to reduce undesir-
able toxic effects, a series of prodrugs of floxuridine has
been developed [143,144]. These amino acid ester pro-
drugs have been shown to target the PEPT1 transporter
[145]. MDCK cells stably transfected with the human
PEPT1 (MDCK/hPEPT1) demonstrated enhanced cell
growth inhibition in the presence of these prodrugs [146].
This prodrug strategy to modify nucleoside drugs seems
to have great potential to improve their tumor selectivity
and drug efficacy.
Amino acid transporters
The transporter-mediated entry of amino acids into cells
is necessary for various cellular functions including pro-
tein synthesis, energy metabolism, glutathione synthesis,
and others. Moreover, amino acids transporters play im-
portant roles in conferring not only drug sensitivity by
mediating the uptake of amino acid analog drugs), but
also drug resistance by promoting the uptake of essential
amino acids for tumor growth and survival. There are 6
major families of amino acid transporters in the solute
carrier (SLC) gene superfamily (SLC1, SLC6, SLC7, SLC36,
SLC38, and SLC43 families) and the orphan SLC16 mono-
carboxylate transporter which transports aromatic amino
acids [147].
Accumulating evidence in the past two decades has
indicated that amino acid availability controls cellular
physiology by altered gene expression levels and signal
transduction pathways in cancer cells. For example, the
mammalian target of rapamycin (mTOR) is a serine/
threonine kinase that regulates fundamental biological
processes and plays critical roles in cell growth regulation
and tumorigenesis [148,149]. The activation of mTOR and
subsequent regulation of mTORC1 is regulated by the up-
take of amino acids such as L-glutamine which has beeninterestingly shown to be transported by the bidirectional
transporters SLC1A5 and SLC7A5 (LAT1) [150]. Regula-
tion of mTOR signaling pathway by modulating the activ-
ity of these amino acid transporters could be an attractive
strategy to control tumor cell survival and progression.
Amino acid transporter system A1 (ATA1), encoded by
SLC38A2, mediates the transport of most small neutral
amino acids, including alanine, serine, and glutamine. The
mRNA level of ATA1 was markedly induced in human
hepatoma cancer cell lines and in patient-derived hepato-
cellular cancer tissues as well. Enhanced expression of
ATA1 is also positively related to the progression of chol-
angiocarcinoma. Furthermore, silencing ATA1 mRNA ex-
pression decreased the viability of HepG2 cells, suggesting
that ATA1 is likely essential to tumor survival [151]. These
studies have indicated the prognostic significance of ATA1
in cancer development and progression and provided
rationales to target ATA1 for cancer therapy.
L-type amino acid transporter 1 (LAT1), encoded by
SLC7A5, is responsible for the transport of large neutral,
aromatic or branched amino acids from extracellular
fluids into the cells. Acivicin is an antineoplastic antibiotic
that targets glutamine-dependent amidotransferases in the
biosynthesis of purines and pyrimidines [152]. The IC50
values for acivicin to inhibit the gabapentin (a LAT1 sub-
strate) accumulation in the stable HEK-LAT1 cells ranged
from 7.9 μM to 340 μM [153]. The experiments of trans-
stimulation and cell-proliferation have demonstrated that
acivicin is likely to be a substrate for LAT1, suggesting
that LAT1 may be targeted for acivicin delivery into tumor
cells [153]. Petel et al. have recently demonstrated that
LAT1 is functionally active in prostate cancer cells (PC-3).
Hence, LAT1 transporter may be used as a target for
improving the availability of poorly permeable but highly
potent anticancer drugs at least in prostate cancer cells
[154].
Conclusions
It is critical to target drugs to tumor cells in order to
improve the clinical efficacy and avoid the adverse ef-
fects of anticancer drugs. The efficacy of chemotherapy
may be largely dependent on the relative activity of
transporters in normal and cancer tissues. In addition
to already extensively investigated efflux transporters,
multiple types of membrane influx transporters, in par-
ticular the SLC superfamily members play very import-
ant roles in conferring sensitivity and resistance to
anticancer agents. These SLC transporters not only dir-
ectly bring anticancer agents into cancer cells but also
serve as the uptake mediators of essential nutrients for
tumor growth and survival. The differential expression
patterns of SLC transporters between normal and tumor
tissues may be well utilized to achieve specific delivery of
chemotherapeutic agents. The transporters may be also
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crease chemosensitivity, for example, via limiting nutrient
supply to cancer cells and regulating their apoptosis and
electrochemical gradients. The SLC transporters expressed
in the intestine, liver and kidney are of particular import-
ance as their activity may be critical to systemic exposure
and disposition of various anticancer agents, serving as a
common basis or determinant for drug-drug interaction,
pharmacological effects, and side effects. The function of
SLC transporters in anticancer drug disposition and action
has been increasingly recognized. However, the major bio-
logical implication and pathophysiological function of these
membrane proteins are far from clear and under extensive
exploration. With advanced knowledge of SLC trans-
porters, their role in the development, optimization, and
personalization of anticancer medicine will be further
underscored and merited.
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